LifeBond’s medical devices incorporate a proprietary adhesive platform technology that functions through the rapid in situ polymerization of structural gelatin. As it polymerizes, the gelatin forms an adhesive and biocompatible hydrogel matrix that adheres strongly to physiological tissue surfaces. The properties of the polymerization process and the hydrogel matrix can be controlled to fit a variety of applications.
LifeBond’s propriety technology is based on the combination of two components of natural origin: Gelatin and microbial transglutaminase (mTG) enzyme. Both components have been used extensively in the food industry for decades and gelatin-based medical devices have been safely implanted in millions of surgical procedures dating back to the 1950s¹.
Gelatin is a derivative of collagen, the most abundant protein in the body. When combined with the mTG enzyme, gelatin is naturally polymerized by formation of inter- and intramolecular chemical bonds between the gelatin molecules. The result is a firm, elastic, hydrogel matrix with unique mechanical properties which is gradually absorbed by the human body.
LifeBond’s technology is unique in that firstly, it is based on components of natural origin and secondly that it allows for the optimization of the polymerized matrix’s mechanical properties.
With customized production processes, the components can be delivered either as a liquid matrix or as dry foam, hence the properties can be modified to fit each desired clinical application.
Both the underlying adhesive formulation and the range of products and applicators developed by LifeBond are thoroughly protected by a robust global IP portfolio.